CD19 and congenital rubella syndrome: Similar to the CRS, among the five subgroups in the anti-CD19 costimulatory domain analysis, CD28ζ (3/17 studies) showed the lowest event rate of ICANS (ER = 0.09; 95% CI = 0.03, 0.16; p = 0.21; I2 = 34.99%), followed by 4-1BB & CD3ζ (3/17 studies) (ER = 0.10; 95% CI = 0.07, 0.14; p = 0.11; I2 = 55.54%), 4-1BB (7/17 studies) (ER = 0.12; 95% CI = 0.07, 0.18; p = 0.15; I2 = 36.50%), CD3ζ & CD28ζ group (2/17 studies) (ER = 0.21; 95% CI = 0.06, 0.35; p = 0.97; I2 = 0.00%), and 4th generation (2/17 studies) (ER = 0.23; 95% CI = 0.12, 0.34; p = 0.31; I2 = 4.16%), respectively.